<DOC>
	<DOCNO>NCT00552929</DOCNO>
	<brief_summary>The objective trial establish dose-response relation Org 25969 give reversal agent rocuronium vecuronium 1-2 PTC sevoflurane anesthesia Caucasian subject</brief_summary>
	<brief_title>A Bridging Trial Comparing Org 25969 1-2 PTC Japanese Caucasian Subjects . Part B : Caucasian Subjects ( 19.4.209B ) ( P05974 )</brief_title>
	<detailed_description />
	<mesh_term>Rocuronium</mesh_term>
	<mesh_term>Vecuronium Bromide</mesh_term>
	<criteria>Subjects ASA class 1 3 ; Subjects least 20 year 65 year age ; Caucasian subject ; Subjects schedule elective surgery require muscle relaxation supine position sevoflurane anesthesia anticipate duration 1.5 3 hour ; Subjects give write informed consent . Exclusion criterion : Subjects difficult intubation anatomical malformation expect ; Subjects know suspect neuromuscular disorder impair NMB and/or significant renal dysfunction ( example creatinine level &gt; 1.6 mg/dl ) and/or severe hepatic dysfunction . Subjects know suspected ( family ) history malignant hyperthermia ; Subjects know suspect allergy narcotic , muscle relaxant medication use general anesthesia ; Subjects receive medication expect interfere rocuronium vecuronium give trial , base dose time administration ; Female subject pregnant ; Female subject childbearing potential use birth control use oral contraception birth control ; Subjects breastfeeding ; Subjects already participate CT 19.4.209B , another trial Org 25969 ; Subjects participate another clinical trial , preapproved Organon , within 6 month enter CT 19.4.209B .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>